Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allergic Asthma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    354 result(s) found for: Allergic Asthma. Displaying page 9 of 18.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2021-003903-16 Sponsor Protocol Number: LPS16676 Start Date*: 2022-02-14
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Placebo controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients with Uncontrolled Moderate to Severe Asthma (ATLAS)
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004731-21 Sponsor Protocol Number: E02/04/SLIT1-M Start Date*: 2006-05-04
    Sponsor Name:ALK-Abelló, S.A.
    Full Title: Estudio doble ciego controlado con placebo para evaluar la eficacia de SLITone en pacientes alérgicos a ácaros de polvo de casa. A randomised, double-blind, placebo-controlled trial assessing the...
    Medical condition: asma por sensibilización a ácaros del polvo doméstico
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003553 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011999-30 Sponsor Protocol Number: VO64.08 Start Date*: 2009-09-16
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets on...
    Medical condition: House Dust Mite Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) ES (Prematurely Ended) HU (Completed) DE (Prematurely Ended) FR (Completed) DK (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001584-66 Sponsor Protocol Number: 1301-PG-PSC-136 Start Date*: 2005-08-29
    Sponsor Name:LETI Pharma GmbH
    Full Title: A randomised controlled multicentre study for the safety of Depigoid(R) rush schedule
    Medical condition: Rhinitis and/or rhinoconjunctivitis without uncontrolled asthma caused by clinical relevant sensitisation againts tree pollen, grass pollen or house dust mites
    Disease: Version SOC Term Classification Code Term Level
    8.0 10001723 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001587-97 Sponsor Protocol Number: SC-322A Start Date*: 2023-04-06
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy
    Medical condition: Patients with birch pollen-related allergic rhinitis/rhinoconjunctivitis and with well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007657-12 Sponsor Protocol Number: ParLais/09 Start Date*: 2009-10-26
    Sponsor Name:LOFARMA
    Full Title: Evaluating the efficacy, safety, tolerability of use and treatment adherence in two different dosing schedules, pre-costagionale and costagionale, of a sublingual allergoid (Lais Parietaria)adminis...
    Medical condition: Subjects with Parietaria pollen allergy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002811-25 Sponsor Protocol Number: DMV03-SIT-027 Start Date*: 2020-11-13
    Sponsor Name:Inmunotek, S.L.
    Full Title: Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjun...
    Medical condition: Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and olive pollen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003538-28 Sponsor Protocol Number: CIGE025AIA05 Start Date*: 2016-02-16
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years)...
    Medical condition: Moderate-severe inadequately controlled Allergic Asthma
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005035-85 Sponsor Protocol Number: 2012RC14 Start Date*: 2013-05-03
    Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside
    Full Title: A proof of concept study in allergic rhinitis, to evaluate the differential effects of doxazosin between single and chronic dosing on nasal airway calibre
    Medical condition: Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003013-34 Sponsor Protocol Number: UOL0730 Start Date*: 2020-03-02
    Sponsor Name:University of Leicester
    Full Title: Beyond Allergic Th2 Severe Asthma
    Medical condition: T2-High and T2-Low severe asthma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10005503 Blood eosinophils LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    21.1 100000004865 10049868 Asthma exacerbation prophylaxis LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-006292-77 Sponsor Protocol Number: SB/0027 Start Date*: 2009-05-08
    Sponsor Name:HAL Allergy
    Full Title: SUBLIVAC® Birch PROBE study
    Medical condition: IgE mediated allergic disorders triggered by birch pollen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001709 Allergic conjunctivitis LLT
    9.1 10001723 Allergic rhinitis LLT
    9.1 10053713 Allergenic desensitisation procedure LLT
    9.1 10053741 Allergenic desensitization procedure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004806-40 Sponsor Protocol Number: MEIN/15/Bil-ARC/001 Start Date*: 2016-03-29
    Sponsor Name:Menarini International Operations Luxembourg S.A.
    Full Title: Bilastine and Montelukast in patients with seasonal allergic rhinoconjunctivitis and asthma: Efficacy of concomitant administration - the SKY study; Acronym: SKY
    Medical condition: Seasonal allergic rhinoconjunctivitis and asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) PL (Completed) LV (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005550-30 Sponsor Protocol Number: SB/0042 Start Date*: 2014-06-10
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled (DBPC), parallel group study to assess the clinical efficacy and safety of SUBLIVAC FIX Birch immunotherapy in patients suffering from allergic rhinit...
    Medical condition: Moderate to severe birch pollen induced allergic rhinitis/rhinoconjunctivitis with or without mild to moderate persistent asthma.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) SK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001795-20 Sponsor Protocol Number: MT-02 Start Date*: 2006-06-29
    Sponsor Name:ALK-Abelló A/S
    Full Title: A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects
    Medical condition: IgE mediated House dust mite induced mild to moderate asthma and mild to severe allergic rhinitis.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) DK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000627-53 Sponsor Protocol Number: P150922 Start Date*: 2016-11-18
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: MAINtenance of remission with RITuximab versus azathioprine for patients with newly-diagnosed or relapsing Eosinophilic Granulomatosis with polyangiitis. A prospective, randomized, controlled, doub...
    Medical condition: Patients with newly diagnosed or relapsing EGPA, after achievement of remission.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10009164 Churg Strauss syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022437-28 Sponsor Protocol Number: 40929837ASH2001 Start Date*: 2010-11-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Efficacy of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model
    Medical condition: JNJ-40929837 is being developed for the treatment of asthma.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002089-42 Sponsor Protocol Number: R1908-1909-ALG-2102 Start Date*: 2021-11-18
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural ...
    Medical condition: Allergic Rhino conjunctivitis due to Cat Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Prematurely Ended) FR (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-000211-26 Sponsor Protocol Number: D5890L00007 Start Date*: 2004-08-04
    Sponsor Name:AstraZeneca AB
    Full Title: A comperative, placebo-controlled, doubleblind, double dummy, cross over, single center phase IIIb study between formoterol alone and the fixed combination of formoterol and budesonide on airway re...
    Medical condition: Patient with stable and mild allergic asthma.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003096-35 Sponsor Protocol Number: WF10-C-2013/R-2-02 Start Date*: 2014-01-10
    Sponsor Name:Nuvo Research GmbH
    Full Title: A multi-centre, randomised, placebo-controlled, double-blind, parallel-group study on the efficacy and safety of WF10 and its main constituents in patients with refractory allergic rhinitis
    Medical condition: refractory allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020079-22 Sponsor Protocol Number: DG40.08 Start Date*: Information not available in EudraCT
    Sponsor Name:STALLERGENES S.A.
    Full Title: Determination of sensitivity and specificity of five solutions of allergen extract (5 grasses, birch, ragweed pollens and Dermatophagoides pteronyssinus and Dermatophagoides farinae mites) for diag...
    Medical condition: Allergy to grass pollen Allergy to birch pollen Allergy to ragweed pollen Allergy to mites
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039085 Rhinitis allergic LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 05 01:20:19 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA